Gilteritinib is currently being prospectively tested as maintenance therapy after allo-HSCT in FLT3-ITD AML patients in an ongoing randomized, double-blind, placebo-controlled phase III trial (NCT02997202) (109). This evidence concerns the gene FLT3 and acute myeloid leukemia.